Login to Your Account



XenoPort Eyeing Restless Leg Syndrome Phase III

By Karen Pihl-Carey


Wednesday, August 3, 2005
Inching closer to a market that, until recently, was virtually untapped, XenoPort Inc. proved in a Phase IIb trial that its restless leg syndrome candidate, XP13512, was significantly better than placebo in relieving patient symptoms. (Bioworld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription